<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03481816</url>
  </required_header>
  <id_info>
    <org_study_id>180073</org_study_id>
    <secondary_id>18-C-0073</secondary_id>
    <nct_id>NCT03481816</nct_id>
  </id_info>
  <brief_title>Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines</brief_title>
  <official_title>Treatment of Patients With Castration Resistant Prostate Cancer Using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Metastatic castration resistant prostate cancer (mCRPC) keeps growing even when the amount of&#xD;
      testosterone in the body is reduced to very low levels. mCRPC is incurable. Researchers want&#xD;
      to develop vaccines to teach the immune system to target and kill cancer cells. They want to&#xD;
      test three of these vaccines (ETBX-071, ETBX-061, and ETBX-051) against mCRPC.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To test the safety of combination ETBX-071, ETBX-061, and ETBX-051 and to study their effects&#xD;
      on the immune system.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      People ages 18 and older with mCRPC that has not responded to standard therapies&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened with:&#xD;
&#xD;
      Medical history&#xD;
&#xD;
      Physical exam&#xD;
&#xD;
      Blood, urine, and heart tests&#xD;
&#xD;
      Computed tomography (CT) or magnetic resonance imaging (MRI) scans&#xD;
&#xD;
      Bone scan&#xD;
&#xD;
      Participants will get the vaccines as shots under the skin every 3 weeks for 3 doses. They&#xD;
      may then have the shots every 8 weeks for up to 1 year.&#xD;
&#xD;
      Participants will keep a diary to record any symptoms from the vaccines.&#xD;
&#xD;
      Participants will have blood tests each time they get the vaccines. They will also have scans&#xD;
      and other tests to measure the effect the vaccines have on their tumors.&#xD;
&#xD;
      Participants will have a visit within 28 days after their last treatment. This includes a&#xD;
      physical exam and blood and urine tests.&#xD;
&#xD;
      Participants will then be contacted by phone every 3 months for the first year, every 6&#xD;
      months for the next 2 years, and every 12 months for another 2 years.&#xD;
&#xD;
      Participants will be asked to join a long-term follow up study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  The overall goal of the current project is to expand our immunotherapeutic approach for&#xD;
           the treatment of prostate cancer employing a multi-targeted approach.&#xD;
&#xD;
        -  Therapeutic cancer vaccines targeting overexpressed proteins offer a potential method to&#xD;
           activate T cells against tumors.&#xD;
&#xD;
        -  A novel adenovirus based vaccines targeting three (3) human tumor associated antigens&#xD;
           (TAA), Prostate specific antigen (PSA), Mucin 1 (MUC1), and brachyury, respectively have&#xD;
           demonstrated anti-tumor cytolytic T cell responses in pre-clinical animal models of&#xD;
           cancer.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      -To determine the overall safety and recommended phase 2 dose of a combination of three&#xD;
      immunotherapeutic vaccines (ETBX-071, ETBX-061, and ETBX-051) when administered&#xD;
      subcutaneously (SC) to subjects with metastatic castration resistant prostate cancer&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Subjects age 18 and older with cytologically or histologically confirmed prostate cancer&#xD;
           for which no curative standard approved therapy is available.&#xD;
&#xD;
        -  Metastatic Castration Resistant Prostate Cancer (mCRPC) patients with rising PSA or&#xD;
           progressive disease despite castration levels of testosterone.&#xD;
&#xD;
        -  Prior treatment with immunotherapy hormonal therapy, radiotherapy, chemotherapy, and/or&#xD;
           other experimental therapy is allowed.&#xD;
&#xD;
        -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1&#xD;
&#xD;
        -  Adequate organ and bone marrow function&#xD;
&#xD;
        -  Subjects with a history of autoimmune disease (active or past) and subjects requiring&#xD;
           systemic steroids are not eligible (physiologic doses of steroids for steroid&#xD;
           replacement as well as nasal, topical and inhaled steroids are allowed).&#xD;
           Autoimmune-related thyroid disease, type I diabetes and vitiligo are permitted if the&#xD;
           condition is well controlled.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  This is a Phase I trial in subjects with mCRPC. A combination of three therapeutic&#xD;
           vaccines (ETBX-071, ETBX-061, and ETBX-051) which use the same modified Adenovirus&#xD;
           vector backbone, separately encoding three well studied TAA,PSA, MUC1, and brachyury,&#xD;
           respectively) will be assessed. The vaccines will be tested at standard dose levels,&#xD;
           with a dose de-escalation (if required) design employed. The dose level of each vaccine&#xD;
           tested will be 5x10 to the eleventh power VP. This dose has been found in a prior phase&#xD;
           1 testing of a similar vaccine Ad5 [E1-, E2b-]-carcinoembryonic antigen (CEA)(6D)&#xD;
           (ETBX-011) to be well tolerated (with no dose-limiting toxicities (DLTs) or related&#xD;
           serious adverse events(SAEs), and be optimal for induction of immune responses.&#xD;
&#xD;
        -  Up to six patients will be enrolled at dose level 1. If less than or equal to 1 of 6&#xD;
           patients experience a DLT, an initiation of the dose expansion phase will occur. If more&#xD;
           than or equal to 2 of 6 experience DLT at dose level 1, then dose de-escalation will&#xD;
           occur. Up to six patients will be enrolled at the lower dose level (-1) (1x10 to the&#xD;
           eleventh power VP). If less than or equal to 1 of 6 patients experience a DLT, then the&#xD;
           maximum tolerated (MTD) will be declared at this dose, and initiation of the dose&#xD;
           expansion phase will occur. If more than or equal to 2 of 6 experience DLT at dose level&#xD;
           -1, then a further dose de-escalation will occur. Up to six patients will be enrolled at&#xD;
           the lower dose level (-2) (5x10 to the tenth power VP). If less than or equal to 1 of 6&#xD;
           patients experience a DLT, then the maximum tolerated (MTD) will be declared at this&#xD;
           dose, and initiation of the dose expansion phase will occur. If more than or equal to 2&#xD;
           of 6 experience DLT at dose level -2, then the study will be stopped.&#xD;
&#xD;
        -  A dose expansion phase of study will be enrolled after the MTD of the vaccines have been&#xD;
           determined. An additional 12 subjects will be enrolled in the dose expansion component&#xD;
           of the trial, for a total of 18 subjects at the MTD.&#xD;
&#xD;
        -  The ETBX-051, ETBX-61 and ETBX-71 vaccines will be administered subcutaneously (SC) at&#xD;
           separate injection sites (proximal limb, preferably the thigh), will be administered SC&#xD;
           every 3 weeks for 3 doses (dose de-escalation cohorts) followed by boosts every 8 weeks&#xD;
           for 1 year (only patients enrolled in dose expansion cohort).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2018</start_date>
  <completion_date type="Actual">March 9, 2021</completion_date>
  <primary_completion_date type="Actual">January 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Dose-Limiting Toxicities</measure>
    <time_frame>4 weeks after receiving the first vaccine dose</time_frame>
    <description>A dose-limiting toxicity is defined as occurring within 28 days after the first vaccine administration and meeting on of these criteria: Any Grade 3 or greater toxicity or any Grade 2 or higher autoimmune reaction as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0; or generalized erythroderma or macular or papular rash.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose</measure>
    <time_frame>Within the first 4 weeks after drug is administered.</time_frame>
    <description>RP2D is the maximum tolerated dose declared after â‰¤1 of 6 participants experience a dose-limiting toxicity within the first 4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Objective Response</measure>
    <time_frame>Objective response at any time point during treatment on study up to 1 year</time_frame>
    <description>ORR is the percentage of subjects who experience partial response (PR) or complete response (CR) measured by the Response Evaluation Criteria in Solid Tumors (RECIST) at any time point during the treatment period. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Disease Control Rate (DCR) Lasting for at Least 6 Months</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>DCR is the percentage of subjects who experience partial response (PR), complete response (CR), or stable disease (SD) lasting for at least 6 months. Response was measured by the Response Evaluation Criteria in Solid Tumors (RECIST)v1. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters while on study. Progressive disease is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progressions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Time from recorded partial response until development of progressive disease. This was accessed every 3 weeks for the first 3 doses and then every 8 weeks up to 1 year (Arm 2)</time_frame>
    <description>Duration of response is the time from when measurement criteria for Partial Response (PR) or Complete Response (CR) are met until disease recurrence or progression per dose cohort. Response was measured by the Response Evaluation Criteria in Solid Tumors (RECIST)v1. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>This was accessed every 3 weeks for the first 3 doses, then every 8 weeks up to 1 year (Arm 2).</time_frame>
    <description>PFS is the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first per dose cohort. Progression was measured by the Response Evaluation Criteria in Solid Tumors (RECIST)v1. Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Every 3 weeks for the first 3 doses, then every 8 weeks up to 1 year then every 3 months for 12 months and then approximately every 6 months every 6 months for 24 months and then every 12 months thereafter for another 24 months.</time_frame>
    <description>OS is the time from the date of first treatment to the date of death (any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Overall Survival (OS) Probability at 12 Months and 24 Months</measure>
    <time_frame>12 and 24 months after first treatment</time_frame>
    <description>Probability of being alive at 12 Months and 24 Months after first vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-Specific Antigen Doubling Time (PSA DT) at Week 14 and End of Study</measure>
    <time_frame>PSA DT was done once at week 14 and the second time at the end of study (any time point within a year while on study when they met criteria for progression)</time_frame>
    <description>PSA DT in participants with advanced cancer treated with the ETBX-071, ETBX-061, and ETBX-051 vaccines were determined using a nomogram to find detectable PSA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)</measure>
    <time_frame>Date treatment consent signed to date off study, approximately 8 months and 30 days for the Arm 1/Dose De-Escalation group, and 10 months and 25 days for the Arm 2/Dose Expansion group.</time_frame>
    <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <condition>Prostatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1/Dose De-Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled to dose de-escalation cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2/Dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-071; adenoviral PSA vaccine</intervention_name>
    <description>5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
    <arm_group_label>Arm 1/Dose De-Escalation</arm_group_label>
    <arm_group_label>Arm 2/Dose expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-061; adenoviral MUC1 vaccine</intervention_name>
    <description>5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
    <arm_group_label>Arm 1/Dose De-Escalation</arm_group_label>
    <arm_group_label>Arm 2/Dose expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-051; adenoviral brachyury vaccine</intervention_name>
    <description>5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
    <arm_group_label>Arm 1/Dose De-Escalation</arm_group_label>
    <arm_group_label>Arm 2/Dose expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Age more than or equal to 18 years (male).&#xD;
&#xD;
          -  Ability to understand and provide signed informed consent that fulfills Institutional&#xD;
             Review Board (IRB)s guidelines.&#xD;
&#xD;
          -  Cytologically or histologically confirmed prostate cancer for which no curative&#xD;
             standard approved therapy is available by either the Laboratory of Pathology at the&#xD;
             National Institutes of Health (NIH) Clinical Center or Walter Reed National Military&#xD;
             Medical Center at Bethesda prior to starting this study. If no pathologic specimen is&#xD;
             available, patients may enroll with a pathologists report showing a histological&#xD;
             diagnosis of prostate cancer and a clinical course consistent with the disease.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
          -  Subjects who have received prior prostate specific antigen (PSA), mucin1 (MUC1),&#xD;
             and/or brachyury-targeted immunotherapy (e.g. vaccine) are eligible for this trial if&#xD;
             this treatment was discontinued at least 3 months prior to enrollment.&#xD;
&#xD;
          -  Resolution of all toxic side effects of prior chemotherapy, radiotherapy, or surgical&#xD;
             procedures to National Cancer Institute (NCI) Common Terminology Criteria for Adverse&#xD;
             Events (CTCAE) Grade less than or equal to1.&#xD;
&#xD;
          -  Adequate hematologic function at screening, as follows:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) greater than or equal to x 10 to the ninth power/L&#xD;
&#xD;
          -  Hemoglobin more than or equa to 9 g/dL&#xD;
&#xD;
          -  Platelets more than or equal to 75,000/microliter.&#xD;
&#xD;
          -  Prothrombin (PT)-international normalized ratio (INR) &lt; 1.5.&#xD;
&#xD;
          -  Partial thromboplastin time (PTT) &lt; 1.5 x upper limit of normal (ULN).&#xD;
&#xD;
          -  Adequate renal and hepatic function at screening, as follows:&#xD;
&#xD;
             --Serum creatine less than or equal to 1.5x upper limit of normal (ULN) OR creatinine&#xD;
             clearance (CrCl) more than or equal to 40mL/min (if using the Cockcroft-Gault formula&#xD;
             below):&#xD;
&#xD;
               1. Female CrCl = [(140 - age in years) x weight in kg x 0.85] / [72 x serum&#xD;
                  creatinine in mg/dL]&#xD;
&#xD;
               2. Male CrCl = [(140 - age in years) x weight in kg x1.00] / [72 x serum creatinine&#xD;
                  in mg/dL]&#xD;
&#xD;
          -  Total bilirubin less than or equal to 1.5 x ULN OR in subjects with Gilberts syndrome,&#xD;
             a total bilirubin less than or equal to x ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal&#xD;
             to 2.5 x ULN, unless liver metastasis are present, then values must be less than or&#xD;
             equal to 5 x ULN)&#xD;
&#xD;
          -  The effects of ETBX-051, ETBX-061 and ETBX-071 vaccines on the developing human fetus&#xD;
             are unknown. For this reason subjects must agree to use a condom and acceptable&#xD;
             contraceptive method with their partner during the study and for one month after the&#xD;
             last dose of vaccines.&#xD;
&#xD;
          -  Ability to attend required study visits and return for adequate follow up, as required&#xD;
             by this protocol.&#xD;
&#xD;
          -  Castrate testosterone level (&lt;50ng/dl or 1.7nmol /L)&#xD;
&#xD;
          -  Metastatic disease documented by at least one of the following:&#xD;
&#xD;
          -  Metastatic bone disease on an imaging study, or&#xD;
&#xD;
          -  Soft tissue disease documented by computed tomography (CT)/magnetic resonance imaging&#xD;
             (MRI)&#xD;
&#xD;
          -  Progressive disease at study entry defined as one or more of the following criteria&#xD;
             occurring in the setting of castrate levels of testosterone:&#xD;
&#xD;
          -  Radiographic progression defined as any new or enlarging bone lesions or growing lymph&#xD;
             node disease, consistent with prostate cancer&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  PSA progression defined by sequence of rising values separated by &gt;1 week (2 separate&#xD;
             increasing values over a minimum of 2ng/ml (Prostrate Cancer Working Group 2 (PCWG2)&#xD;
             PSA eligibility criteria). If patients had been on flutamide, PSA progression is&#xD;
             documented 4 weeks or more after withdrawal. For patients on bicalutamide or&#xD;
             nilutamide disease progression is documented 6 or more weeks after withdrawal. The&#xD;
             requirement for a 4-6 week withdrawal period following discontinuation of flutamide,&#xD;
             nilutamide or bicalutamide only applies to patients who have been on these drugs for&#xD;
             at least the prior 6 months. For all other patients, they must stop bicalutamide,&#xD;
             nilutamide or flutamide the day prior to enrollment.&#xD;
&#xD;
          -  Patients must agree to continue to continuation of androgen deprivation therapy (ADT)&#xD;
             with a gonadotropin-releasing hormone analogue/antagonist or bilateral orchiectomy&#xD;
&#xD;
          -  Prior treatment with immunotherapy, hormonal therapy, radium 223, chemotherapy and/or&#xD;
             other experimental therapy is allowed.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Treatment with an investigational drug study within 28 days of before starting on&#xD;
             study treatment.&#xD;
&#xD;
          -  Subjects with concurrent cytotoxic chemotherapy or radiation therapy. There must be at&#xD;
             least 28 days between any other prior chemotherapy (or radiotherapy) and study&#xD;
             treatment. Prior antibody therapy must be discontinued 8 weeks prior to start of study&#xD;
             treatment. Prior hormonal therapy can be discontinued 24 hours prior to start of study&#xD;
             treatment.&#xD;
&#xD;
          -  Any prior PSA, MUC1, and/or brachyury-targeted immunotherapy (e.g., vaccine) must have&#xD;
             been discontinued at least 12 weeks before initiation of study treatment. Subjects&#xD;
             must have recovered from all acute toxicities from prior treatment prior to screening&#xD;
             for this study.&#xD;
&#xD;
          -  Prior treatment with Adenovirus-Based vectors immunotherapy&#xD;
&#xD;
          -  Known active brain or central nervous system metastasis, or seizures requiring&#xD;
             anticonvulsant treatment, cerebrovascular accident, or transient ischemic attack (&lt; 6&#xD;
             months prior to enrollment).&#xD;
&#xD;
          -  Subjects with a history of autoimmune disease (active or past), such as but not&#xD;
             restricted to inflammatory bowel disease, systemic lupus erythematosus, ankylosing&#xD;
             spondylitis, scleroderma, or multiple sclerosis. Autoimmune-related thyroid disease,&#xD;
             type I diabetes and vitiligo are permitted if the condition is well controlled.&#xD;
&#xD;
          -  Subjects with serious intercurrent chronic or acute illness, such as cardiac or&#xD;
             pulmonary disease, hepatic disease, or other illness considered by the Investigator as&#xD;
             high risk for investigational drug treatment.&#xD;
&#xD;
          -  Subjects with a history of heart disease, such as congestive heart failure (class II,&#xD;
             III, or IV defined by the New York Heart Association functional classification),&#xD;
             history of unstable or poorly controlled angina, or history (&lt; 1 year prior to&#xD;
             enrollment) of ventricular arrhythmia.&#xD;
&#xD;
          -  Subjects with a medical or psychological impediment that would impair the ability of&#xD;
             the subject to receive therapy per protocol or impact ability to comply with the&#xD;
             protocol or protocol-required visits and procedures.&#xD;
&#xD;
          -  Presence of a known active acute or chronic infection, including human&#xD;
             immunodeficiency virus (HIV, as determined by enzyme-linked immunosorbent assay&#xD;
             [ELISA] and confirmed by western blot) and hepatitis B and hepatitis C virus (HBV/HCV,&#xD;
             as determined by Hepatitis B surface antigen (HBsAg) and hepatitis C serology).&#xD;
&#xD;
          -  Subjects on systemic intravenous or oral steroid therapy (or other immunosuppressive,&#xD;
             such as azathioprine or cyclosporin A) are excluded on the basis of potential immune&#xD;
             suppression. Subjects must have had at least 6 weeks of discontinuation of any steroid&#xD;
             therapy (except that used as premedication for chemotherapy or contrast-enhanced&#xD;
             studies) prior to enrollment. Physiologic (replacement) doses of steroids as well as&#xD;
             nasal, topical or inhaled steroids are allowed.&#xD;
&#xD;
          -  Subjects with known allergy or hypersensitivity to any component of the&#xD;
             investigational product will be excluded.&#xD;
&#xD;
          -  Subjects with acute or chronic skin disorders that will interfere with injection into&#xD;
             the skin of the extremities or subsequent assessment of potential skin reactions will&#xD;
             be excluded.&#xD;
&#xD;
          -  Subjects vaccinated with a live (attenuated) vaccine (e.g., FluMist) or a killed&#xD;
             (inactivated)/subunit vaccine (e.g., PNEUMOVAX, Fluzone) within 28 days or 14 days,&#xD;
             respectively, of the first planned dose of ETBX vaccine.&#xD;
&#xD;
          -  Patients with second malignancy within 3 years of enrollment; Patients curatively&#xD;
             treated non-melanoma skin cancers or carcinoma in situ of the bladder, are not&#xD;
             excluded.&#xD;
&#xD;
          -  Use of herbal products that may decrease PSA levels (e.g. saw palmetto)&#xD;
&#xD;
          -  Patients who have received radiation therapy, radionuclide therapy or undergone&#xD;
             surgery within certain duration (4 weeks) of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marijo Bilusic, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2018-C-0073.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <results_first_submitted>September 25, 2020</results_first_submitted>
  <results_first_submitted_qc>November 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 22, 2020</results_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>Marijo Bilusic, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>mCRPC</keyword>
  <keyword>Therapeutic Cancer Vaccines</keyword>
  <keyword>ETBX-071</keyword>
  <keyword>ETBX-061</keyword>
  <keyword>ETBX-051</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT03481816/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT03481816/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1/Dose De-escalation</title>
          <description>Subjects enrolled to dose de-escalation cohorts. We did not need to dose de-escalate since none of patient's had dose limiting toxicity (DLT) so all patients received planned higher starting dose.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2/Dose Expansion</title>
          <description>Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Starting Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Refused further vaccines after 1 dose</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Dose Expansion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Off treatment due to progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>We did not need to dose de-escalate since none of patient's had dose limiting toxicity (DLT) so all patients received planned higher starting dose in Arm 1/Dose De-escalation Arm/Group.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1/Dose De-Escalation</title>
          <description>Subjects enrolled to dose de-escalation cohorts.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2/Dose Expansion</title>
          <description>Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.62" spread="8.6"/>
                    <measurement group_id="B2" value="72.58" spread="9.23"/>
                    <measurement group_id="B3" value="71.60" spread="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median Baseline Prostate-Specific Antigen (PSA)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.92" lower_limit="8.01" upper_limit="1006"/>
                    <measurement group_id="B2" value="14.55" lower_limit="0.65" upper_limit="605"/>
                    <measurement group_id="B3" value="25.58" lower_limit="0.65" upper_limit="1006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose-Limiting Toxicities</title>
        <description>A dose-limiting toxicity is defined as occurring within 28 days after the first vaccine administration and meeting on of these criteria: Any Grade 3 or greater toxicity or any Grade 2 or higher autoimmune reaction as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0; or generalized erythroderma or macular or papular rash.</description>
        <time_frame>4 weeks after receiving the first vaccine dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/Dose De-Escalation</title>
            <description>Subjects enrolled to dose de-escalation cohorts. We did not need to dose de-escalate since none of patient's had dose limiting toxicity (DLT) so all patients received planned higher starting dose.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2/Dose Expansion</title>
            <description>Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose-Limiting Toxicities</title>
          <description>A dose-limiting toxicity is defined as occurring within 28 days after the first vaccine administration and meeting on of these criteria: Any Grade 3 or greater toxicity or any Grade 2 or higher autoimmune reaction as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0; or generalized erythroderma or macular or papular rash.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase 2 Dose</title>
        <description>RP2D is the maximum tolerated dose declared after â‰¤1 of 6 participants experience a dose-limiting toxicity within the first 4 weeks.</description>
        <time_frame>Within the first 4 weeks after drug is administered.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/Dose De-Escalation</title>
            <description>Subjects enrolled to dose de-escalation cohorts.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase 2 Dose</title>
          <description>RP2D is the maximum tolerated dose declared after â‰¤1 of 6 participants experience a dose-limiting toxicity within the first 4 weeks.</description>
          <units>viral particles</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500000000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Objective Response</title>
        <description>ORR is the percentage of subjects who experience partial response (PR) or complete response (CR) measured by the Response Evaluation Criteria in Solid Tumors (RECIST) at any time point during the treatment period. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm.</description>
        <time_frame>Objective response at any time point during treatment on study up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/Dose De-Escalation</title>
            <description>Subjects enrolled to dose de-escalation cohorts. We did not need to dose de-escalate since none of patient's had dose limiting toxicity (DLT) so all patients received planned higher starting dose.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2/Dose Expansion</title>
            <description>Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Objective Response</title>
          <description>ORR is the percentage of subjects who experience partial response (PR) or complete response (CR) measured by the Response Evaluation Criteria in Solid Tumors (RECIST) at any time point during the treatment period. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Disease Control Rate (DCR) Lasting for at Least 6 Months</title>
        <description>DCR is the percentage of subjects who experience partial response (PR), complete response (CR), or stable disease (SD) lasting for at least 6 months. Response was measured by the Response Evaluation Criteria in Solid Tumors (RECIST)v1. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters while on study. Progressive disease is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progressions.</description>
        <time_frame>6 months post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/Dose De-Escalation</title>
            <description>Subjects enrolled to dose de-escalation cohorts. We did not need to dose de-escalate since none of patient's had dose limiting toxicity (DLT) so all patients received planned higher starting dose.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2/Dose Expansion</title>
            <description>Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Disease Control Rate (DCR) Lasting for at Least 6 Months</title>
          <description>DCR is the percentage of subjects who experience partial response (PR), complete response (CR), or stable disease (SD) lasting for at least 6 months. Response was measured by the Response Evaluation Criteria in Solid Tumors (RECIST)v1. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters while on study. Progressive disease is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progressions.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response is the time from when measurement criteria for Partial Response (PR) or Complete Response (CR) are met until disease recurrence or progression per dose cohort. Response was measured by the Response Evaluation Criteria in Solid Tumors (RECIST)v1. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions.</description>
        <time_frame>Time from recorded partial response until development of progressive disease. This was accessed every 3 weeks for the first 3 doses and then every 8 weeks up to 1 year (Arm 2)</time_frame>
        <population>Per protocol, this outcome measure was pre-specified to be performed in Arm 2 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 2/Dose Expansion</title>
            <description>Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response is the time from when measurement criteria for Partial Response (PR) or Complete Response (CR) are met until disease recurrence or progression per dose cohort. Response was measured by the Response Evaluation Criteria in Solid Tumors (RECIST)v1. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions.</description>
          <population>Per protocol, this outcome measure was pre-specified to be performed in Arm 2 only.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="NA" upper_limit="NA">The full range cannot be calculated because we need at least two values. 1/12 participants had a response and was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS is the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first per dose cohort. Progression was measured by the Response Evaluation Criteria in Solid Tumors (RECIST)v1. Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions.</description>
        <time_frame>This was accessed every 3 weeks for the first 3 doses, then every 8 weeks up to 1 year (Arm 2).</time_frame>
        <population>Per protocol, this outcome measure was pre-specified to be performed in Arm 2 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 2/Dose Expansion</title>
            <description>Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS is the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first per dose cohort. Progression was measured by the Response Evaluation Criteria in Solid Tumors (RECIST)v1. Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions.</description>
          <population>Per protocol, this outcome measure was pre-specified to be performed in Arm 2 only.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="19.1" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS is the time from the date of first treatment to the date of death (any cause).</description>
        <time_frame>Every 3 weeks for the first 3 doses, then every 8 weeks up to 1 year then every 3 months for 12 months and then approximately every 6 months every 6 months for 24 months and then every 12 months thereafter for another 24 months.</time_frame>
        <population>Median OS not reached. Per protocol we have to assess Overall survival (OS) - the time from the date of first treatment to the date of death (any cause) per dose cohort and overall.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/Dose De-Escalation</title>
            <description>Subjects enrolled to dose de-escalation cohorts. We did not need to dose de-escalate since none of patient's had dose limiting toxicity (DLT) so all patients received planned higher starting dose.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2/Dose Expansion</title>
            <description>Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS is the time from the date of first treatment to the date of death (any cause).</description>
          <population>Median OS not reached. Per protocol we have to assess Overall survival (OS) - the time from the date of first treatment to the date of death (any cause) per dose cohort and overall.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="3.3" upper_limit="NA">There is no upper end with &quot;not estimable&quot;.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median OS not reached as no events occurred (all patients are alive)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Overall Survival (OS) Probability at 12 Months and 24 Months</title>
        <description>Probability of being alive at 12 Months and 24 Months after first vaccine.</description>
        <time_frame>12 and 24 months after first treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/Dose De-Escalation</title>
            <description>Subjects enrolled to dose de-escalation cohorts. We did not need to dose de-escalate since none of patient's had dose limiting toxicity (DLT) so all patients received planned higher starting dose.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2/Dose Expansion</title>
            <description>Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Overall Survival (OS) Probability at 12 Months and 24 Months</title>
          <description>Probability of being alive at 12 Months and 24 Months after first vaccine.</description>
          <units>Percentage of probability</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="11.1" upper_limit="80.4"/>
                    <measurement group_id="O2" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="4.6" upper_limit="67.6"/>
                    <measurement group_id="O2" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate-Specific Antigen Doubling Time (PSA DT) at Week 14 and End of Study</title>
        <description>PSA DT in participants with advanced cancer treated with the ETBX-071, ETBX-061, and ETBX-051 vaccines were determined using a nomogram to find detectable PSA.</description>
        <time_frame>PSA DT was done once at week 14 and the second time at the end of study (any time point within a year while on study when they met criteria for progression)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/Dose De-Escalation</title>
            <description>Subjects enrolled to dose de-escalation cohorts. We did not need to dose de-escalate since none of patient's had dose limiting toxicity (DLT) so all patients received planned higher starting dose.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2/Dose Expansion</title>
            <description>Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate-Specific Antigen Doubling Time (PSA DT) at Week 14 and End of Study</title>
          <description>PSA DT in participants with advanced cancer treated with the ETBX-071, ETBX-061, and ETBX-051 vaccines were determined using a nomogram to find detectable PSA.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">The first 6 patients completed study after 6 weeks, therefore we did not calculate PSA DT at end of study treatment).</measurement>
                    <measurement group_id="O2" value="2.4" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">The first 6 patients completed study after 6 weeks, therefore we did not calculate PSA DT at end of study treatment).</measurement>
                    <measurement group_id="O2" value="4.3" spread="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)</title>
        <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>Date treatment consent signed to date off study, approximately 8 months and 30 days for the Arm 1/Dose De-Escalation group, and 10 months and 25 days for the Arm 2/Dose Expansion group.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/Dose De-Escalation</title>
            <description>Subjects enrolled to dose de-escalation cohorts. We did not need to dose de-escalate since none of patient's had dose limiting toxicity (DLT) so all patients received planned higher starting dose.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2/Dose Expansion</title>
            <description>Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)</title>
          <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study, approximately 8 months and 30 days for the Arm 1/Dose De-Escalation group, and 10 months and 25 days for the Arm 2/Dose Expansion group.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1/Dose De-Escalation</title>
          <description>Subjects enrolled to dose de-escalation cohorts.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2/Dose Expansion</title>
          <description>Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.&#xD;
ETBX-071; adenoviral PSA vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-061; adenoviral MUC1 vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.&#xD;
ETBX-051; adenoviral brachyury vaccine: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (5.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (5.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hemorrhoidal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="22" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marijo Bilusic</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>240-760-6064</phone>
      <email>marijo.bilusic@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

